LIVIMMUNE
CytoDyn Inc.
Mark For: LIVIMMUNE® trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 88751607 |
| Registration Number | 1558751 |
| Mark Literal Elements | LIVIMMUNE |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | TRADEMARK. SERVICE MARK |
| Register | PRINCIPAL |
| Current Location | INTENT TO USE SECTION 2020-08-04 |
| Basis | 1(b) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | Yes |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Jared M. Barrett |
| Attorney Docket Number | 230042.205 |
Timeline
| 2020-01-08 | Application Filed |
| 2020-01-11 | Location: NEW APPLICATION PROCESSING |
| 2020-01-11 | Status: Live/Pending |
| 2020-01-11 | Transaction Date |
| 2020-06-09 | Published |
| 2020-08-04 | Location: INTENT TO USE SECTION |
| 2023-09-04 | Status: Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all docume |
Trademark Parties (Applicants & Owners)
| Party: |  CytoDyn Inc. |
| Address | 1111 Main Street, Suite 660 Vancouver, WASHINGTON UNITED STATES 98660 |
| Legal Entity Type | Corporation |
| Legal Entity State | DELAWARE |
Documents
DrawingAttorney of Record
Good, Services, and Codes
(ABANDONED)
IC 005. US 006 018 044 046 051 052. G & S: Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor(ABANDONED)
IC 042. US 100 101. G & S: Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor(ABANDONED)
IC 044. US 100 101. G & S: Providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| International Codes: | 44 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Therapeutic preparations; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | 2023-09-05 | |
| ABANDONMENT - NO USE STATEMENT FILED | 2023-09-04 | 99999 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2023-02-08 | |
| SOU EXTENSION 5 GRANTED | 2023-02-07 | 70565 |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2023-01-26 | 70565 |
| TEAS EXTENSION RECEIVED | 2023-01-11 | |
| SOU TEAS EXTENSION RECEIVED | 2023-01-11 | |
| SOU EXTENSION 5 FILED | 2023-01-11 | 70565 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2022-06-28 | |
| TEAS EXTENSION RECEIVED | 2022-06-24 | |
| SOU TEAS EXTENSION RECEIVED | 2022-06-24 | |
| SOU EXTENSION 4 GRANTED | 2022-06-24 | 98765 |
| SOU EXTENSION 4 FILED | 2022-06-24 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2022-02-01 | |
| TEAS EXTENSION RECEIVED | 2022-01-28 | |
| SOU TEAS EXTENSION RECEIVED | 2022-01-28 | |
| SOU EXTENSION 3 GRANTED | 2022-01-28 | 98765 |
| SOU EXTENSION 3 FILED | 2022-01-28 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-07-15 | |
| TEAS EXTENSION RECEIVED | 2021-07-13 | |
| SOU TEAS EXTENSION RECEIVED | 2021-07-13 | |
| SOU EXTENSION 2 GRANTED | 2021-07-13 | 98765 |
| SOU EXTENSION 2 FILED | 2021-07-13 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-01-12 | |
| TEAS EXTENSION RECEIVED | 2021-01-08 | |
| SOU TEAS EXTENSION RECEIVED | 2021-01-08 | |
| SOU EXTENSION 1 GRANTED | 2021-01-08 | 98765 |
| SOU EXTENSION 1 FILED | 2021-01-08 | 98765 |
| EXTENSION 1 GRANTED | 2021-01-08 | 98765 |
| EXTENSION 1 FILED | 2021-01-08 | 98765 |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2020-08-04 | |
| PUBLISHED FOR OPPOSITION | 2020-06-09 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2020-06-09 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2020-05-20 | |
| ASSIGNED TO LIE | 2020-05-04 | 68123 |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2020-04-24 | 6328 |
| EXAMINERS AMENDMENT E-MAILED | 2020-04-24 | 6328 |
| EXAMINERS AMENDMENT -WRITTEN | 2020-04-24 | 73371 |
| EXAMINER'S AMENDMENT ENTERED | 2020-04-24 | 88888 |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2020-04-24 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2020-04-22 | 88889 |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2020-04-21 | |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2020-04-21 | 88889 |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2020-03-28 | 6325 |
| NON-FINAL ACTION WRITTEN | 2020-03-28 | 73371 |
| NON-FINAL ACTION E-MAILED | 2020-03-28 | 6325 |
| ASSIGNED TO EXAMINER | 2020-03-26 | 73371 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2020-01-13 | |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | 2020-01-13 | |
| NEW APPLICATION ENTERED IN TRAM | 2020-01-11 | |
| NEW APPLICATION ENTERED | 2020-01-11 |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 LIVIMMUNE 98115520 not registered Live/Pending |
CytoDyn Inc. 2023-08-03 |
 LIVIMMUNE 88751607 not registered Live/Pending |
CytoDyn Inc. 2020-01-08 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 